SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address unmet medical needs.

Our most advanced clinical candidate, SCY-078, is being developed as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections (IFI) in humans.


Our antifungal program is focused on the treatment of serious fungal infections in humans.


Our virology and dry eye clinical compounds are the most advanced candidates from our cyclophilin inhibitor platform.


We leverage our expertise in screening and early drug development to deliver R&D solutions to our animal health partners.

Fully-integrated Drug Discovery & Development Solutions